bearish

Sino Biopharmaceutical (1177.HK) - Three “Golden Eggs” and the Risks Behind

360 Views19 Apr 2022 08:54
Sino Biopharma is lucky to have three “golden eggs”  to contribute huge performance over the years. But its weak pipeline and other destabilizing factors would prevent it from getting high valuation.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
x